Anti-HLA-A02:01 EBV-LMP2A Antibody, clone MAB243

Latent membrane protein 2 (UniProt: P13285; also known as Terminal protein) is encoded by the LMP2 gene (Gene ID: 3783751) in Epstein-Barr virus. EBV is a gamma-herpesvirus, a causative agent of infectious mononucleosis. In healthy individuals, EBV typically establishes a persistent latent infection in which the virus can be detected in resting, nonproliferating peripheral B-lymphocytes. These latently infected cells express only 2 virally encoded genes, LMP2A and EBNA1. Although the majority of virus infected individuals remain healthy, EBV has been implicated in the pathogenesis of African Burkitt s lymphoma and nasopharyngeal carcinoma. LMP2A, a multi-pass membrane protein, localizes in plasma membrane lipid rafts. It maintains EBV latent infection of B cells by preventing lytic reactivation of the virus in response to surface immunoglobulin (sIg) cross-linking. It acts like a dominant negative inhibitor of the sIg-associated protein tyrosine kinases, LYN and SYK. It is also reported to block the translocation of the B-cell antigen receptor (BCR) into lipid rafts, which prevents the subsequent signaling and accelerated internalization of the BCR upon BCR cross-linking. It also serves as a molecular scaffold to recruit SYK, LYN and E3 protein-ubiquitin ligases leading to ubiquitination and degradation of these tyrosine kinases. LMP2A also exhibits a constitutive signaling activity in non-transformed cells, inducing bypass of normal B lymphocyte developmental checkpoints, which allows immunoglobulin-negative cells to colonize peripheral lymphoid organs. (Ref.: Lai, J., et al. (2017). Sci. Rep. 7; 9923; Rancan, C., et al. (2015). PLoS Pathol. 11(6); e1004906).

Clone MAB423 (L2) is a mouse monoclonal antibody that detects EBV-LMP2A. It targets an epitope within 9 amino acids from the C-terminal region.

HLA-A201 with EBV (strain B95-8) LMP2A (CLGGLLTMV) 426-434 recombinant protein.

Quality Control Testing

Evaluated by Flow Cytometry in T2 cells pulsed with LMP2 peptide (426-434).

Flow Cytometry Analysis (FC): 1 μg of this antibody detected HLA-A2-EBV LMP2A in one million T2 cells pulsed with LMP2 peptide (426-434).

Tested Applications

ELISA Analysis: A representative lot detected HLA-A02:01 EBV-LMP2A in ELISA applications (Lai, J., et al. (2016). Blood. 128(10):1396-407; Lai, J., et al. (2017). Sci Rep. 7(1):9923).

Immunohistochemistry Applications: A representative lot detected HLA-A02:01 EBV-LMP2A in Immunohistochemistry applications (Lai, J., et al. (2016). Blood. 128(10):1396-407).

Western Blotting Analysis: A representative lot detected HLA-A02:01 EBV-LMP2A in Western Blotting applications (Lai, J., et al. (2016). Blood. 128(10):1396-407).

Flow Cytometry Analysis: A representative lot detected HLA-A02:01 EBV-LMP2A in Flow Cytometry applications (Lai, J., et al. (2016). Blood.;128(10):1396-407; Lai, J., et al. (2017). Sci Rep.;7(1):9923).

Immunofluorescence Analysis: A representative lot detected HLA-A02:01 EBV-LMP2A in Immunofluorescence applications (Lai, J., et al. (2016). Blood. 128(10):1396-407).

Immunocytochemistry Analysis: A representative lot detected HLA-A02:01 EBV-LMP2A in Immunocytochemistry applications (Lai, J., et al. (2016). Blood. 128(10):1396-407).

Note: Actual optimal working dilutions must be determined by end user as specimens, and experimental conditions may vary with the end user

Anti-HLA-A02:01 EBV-LMP2A, clone MAB243, Cat. No. MABF2302, is a mouse monoclonal antibody that detects EBV-LMP2A and is tested for use in ELISA, Flow Cytometry, Immunocytochemistry, Immunofluorescence, Immunohistochemistry, and Western Blotting.

Purified mouse monoclonal antibody IgG1 in buffer containing 0.1 M Tris-Glycine (pH 7.4), 150 mM NaCl with 0.05% sodium azide.

Recommended storage: +2°C to +8°C.

Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.

Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.